Novartis agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company ...

Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in late-stage clinical testing to prevent complications in patients with atrial ...

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...

Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal For over 30 years, Congress has imposed price ceilings on prescription drugs ...

Turn your Blackstone Griddle into an outdoor pizza oven with this Blackstone On-The-Go Pizza Oven Conversion Kit that’s marked down at Walmart. Walmart has the Blackstone 22-Inch On-the-Go Pizza ...

The popular Blackstone On the Go Griddle always seems to be sold out — but Walmart now has it in stock and on sale, so you can grab it time for spring. The Blackstone On the Go 22-Inch Scissor ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its ...

February 11, 2025 Novartis buys Blackstone's Anthos for up to $3.1 billion Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...